Replies to post #420084 on Anavex Life Sciences Corp (AVXL)

[Kb1123]

Where are you getting 4 Billion revenue for ReTT from?

[RedShoulder]

One other point...

It is not uncommon for the market to give pharmaceutical companies a multiple of approximately 5x their gross revenue.

If Anavex treats just half the Rett population in the US, we would generate approx $4 Billion x 5x multiple = $20 Billion per year market cap.

Divide $20 Billion by 100 million shares and you get $200/share.

To add to Rett's figures Fragile X is around 5 times more patient population than Rett, and will not be that far behind as the trials will be short like Rett. Dr. Randi Hagerman will be running the Fragile X trial. So whatever one figures the revenue for Rett, you can multiply that figure by 5 to add in Fragile X revenues.

Dr Hagerman: "I do a lot of research also in Fragile X syndrome and this medication can improve the Fragile X symptoms in the mouse model of Fragile X so I’m very excited about this medication causing improvements not just in Rett Syndrome but in other neuro-developmental disorders and neurodegenerative disorders.

I am very excited about this medication and also as I age I would definitely like to take Anavex myself."

"I’m excited that this is a break through medication and for not just Rett Syndrome but other disorders of aging and also neuro-degeneration."

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630